Clene (CLNN) Stock Forecast, Price Target & Predictions


OverviewRevenueOwnershipFinancialsChart

CLNN Stock Forecast


Clene stock forecast is as follows: an average price target of $10.00 (represents a 76.37% upside from CLNN’s last price of $5.67) and a rating consensus of 'Buy', based on 6 wall street analysts offering a 1-year stock forecast.

CLNN Price Target


The average price target for Clene (CLNN) is $10.00 based on 1-year price targets from 6 Wall Street analysts in the past 3 months, with a price target range of $10.00 to $10.00. This represents a potential 76.37% upside from CLNN's last price of $5.67.

CLNN Analyst Ratings


Buy

According to 6 Wall Street analysts, Clene's rating consensus is 'Buy'. The analyst rating breakdown for CLNN stock is 0 'Strong Buy' (0.00%), 6 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Clene Price Target by Analyst


DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
May 02, 2022Sumant KulkarniCanaccord Genuity$10.00$2.93241.30%76.37%
Row per page
Go to

The latest Clene stock forecast, released on May 02, 2022 by Sumant Kulkarni from Canaccord Genuity, set a price target of $10.00, which represents a 241.30% increase from the stock price at the time of the forecast ($2.93), and a 76.37% increase from CLNN last price ($5.67).

Clene Price Target by Period


1M3M12M
# Anlaysts---
Avg Price Target---
Last Closing Price$5.67$5.67$5.67
Upside/Downside-100.00%-100.00%-100.00%

In the current month, the average price target of Clene stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Clene's last price of $5.67. This month's average price target is down NaN% compared to last quarter, and down NaN% compared to last year.

Analyst Ratings Upgrades/Downgrades


DateCompanyPrevious RatingNew RatingRating Change
Oct 04, 2024Canaccord GenuityBuyBuyHold
Sep 17, 2024H.C. WainwrightBuyBuyHold
Sep 10, 2024EF Hutton-BuyInitialise
Aug 06, 2024Rodman & RenshawBuyBuyHold
Aug 06, 2024H.C. WainwrightBuyBuyHold
Jun 18, 2024H.C. WainwrightBuyBuyHold
May 23, 2024H.C. WainwrightBuyBuyHold
Apr 17, 2024BenchmarkUnderperformUnderperformHold
Apr 17, 2024H.C. WainwrightBuyBuyHold
Mar 13, 2024H.C. WainwrightBuyBuyHold
Row per page
Go to

Clene's last stock rating was published by Canaccord Genuity on Oct 04, 2024. The company gave CLNN a "Buy" rating, the same as its previous rate.

Clene Financial Forecast


Clene Revenue Forecast

Dec 28Sep 28Jun 28Mar 28Dec 27Sep 27Jun 27Mar 27Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21
Revenue--------------------$170.00K$108.00K-$107.00K$234.00K$174.00K$35.00K$30.00K$199.00K$110.00K
Avg Forecast$256.74K$242.37K$228.80K$215.98K$203.89K$192.47K$181.70K$171.52K$161.92K$152.85K$144.29K$136.21K$50.00K$50.00K$50.00K$50.00K$143.33K$106.67K$120.00K$162.50K$145.00K$136.00K$117.83K$134.17K$181.00K$86.67K$83.33K$83.00K$116.25K$116.25K
High Forecast$256.74K$242.37K$228.80K$215.98K$203.89K$192.47K$181.70K$171.52K$161.92K$152.85K$144.29K$136.21K$50.00K$50.00K$50.00K$50.00K$143.33K$106.67K$120.00K$162.75K$165.71K$136.00K$117.83K$134.17K$181.00K$86.67K$83.33K$83.00K$116.25K$116.25K
Low Forecast$256.74K$242.37K$228.80K$215.98K$203.89K$192.47K$181.70K$171.52K$161.92K$152.85K$144.29K$136.21K$50.00K$50.00K$50.00K$50.00K$143.33K$96.97K$120.00K$162.25K$124.28K$136.00K$117.83K$134.17K$181.00K$86.67K$83.33K$83.00K$116.25K$116.25K
# Analysts111122222222111124212111111111
Surprise %--------------------1.17%0.79%-0.80%1.29%2.01%0.42%0.36%1.71%0.95%

Clene's average Quarter revenue forecast for Mar 24 based on 1 analysts is $162.50K, with a low forecast of $162.25K, and a high forecast of $162.75K. CLNN's average Quarter revenue forecast represents a -4.41% decrease compared to the company's last Quarter revenue of $170.00K (Dec 23).

Clene EBITDA Forecast

Dec 28Sep 28Jun 28Mar 28Dec 27Sep 27Jun 27Mar 27Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21
# Analysts111122222222111124212111111111
EBITDA--------------------$-9.51M$-9.54M-$-10.24M$-10.21M$-8.24M$-12.89M$-12.71M$4.80M$29.19M
Avg Forecast$-154.04K$-145.42K$-137.28K$-129.59K$-122.33K$-115.48K$-109.02K$-102.91K$-97.15K$-91.71K$-86.58K$-81.73K$-30.00K$-30.00K$-30.00K$-30.00K$-86.00K$-64.00K$-72.00K$-97.50K$-87.00K$-81.60K$-70.70K$-80.50K$-108.60K$-52.00K$-50.00K$-10.00$-69.75K$-69.75K
High Forecast$-154.04K$-145.42K$-137.28K$-129.59K$-122.33K$-115.48K$-109.02K$-102.91K$-97.15K$-91.71K$-86.58K$-81.73K$-30.00K$-30.00K$-30.00K$-30.00K$-86.00K$-58.18K$-72.00K$-97.35K$-74.57K$-81.60K$-70.70K$-80.50K$-108.60K$-52.00K$-50.00K$-8.00$-69.75K$-69.75K
Low Forecast$-154.04K$-145.42K$-137.28K$-129.59K$-122.33K$-115.48K$-109.02K$-102.91K$-97.15K$-91.71K$-86.58K$-81.73K$-30.00K$-30.00K$-30.00K$-30.00K$-86.00K$-64.00K$-72.00K$-97.65K$-99.43K$-81.60K$-70.70K$-80.50K$-108.60K$-52.00K$-50.00K$-13.00$-69.75K$-69.75K
Surprise %--------------------109.29%116.94%-127.20%94.04%158.44%257.85%1271000.00%-68.85%-418.49%

1 analysts predict CLNN's average Quarter EBITDA for Mar 22 to be $-10.00, with a high of $-8.00 and a low of $-13.00. This is -100.00% lower than Clene's previous annual EBITDA (Dec 21) of $4.80M.

Clene Net Income Forecast

Dec 28Sep 28Jun 28Mar 28Dec 27Sep 27Jun 27Mar 27Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21
# Analysts111122222222111124212111111111
Net Income--------------------$-10.17M$-2.42M-$-13.87M$8.62M$-12.13M$3.90M$-14.08M$4.42M$28.94M
Avg Forecast$-24.32M$-21.93M$-20.37M$-21.48M$-30.02M$-27.07M$-25.15M$-26.51M$-29.83M$-26.90M$-24.99M$-41.39M$-79.44M$-87.78M$-88.69M$-90.96M$-123.63M$-170.93M$-193.77M$-205.54M$-184.99M$-231.23M$-316.86M$-372.09M$-88.09M$-554.23M$-515.74M$-11.00$-416.22M$-518.99M
High Forecast$-24.32M$-21.93M$-20.37M$-21.48M$-30.02M$-27.07M$-25.15M$-26.51M$-29.83M$-26.90M$-24.99M$-41.39M$-79.44M$-87.78M$-88.69M$-90.96M$-123.63M$-168.38M$-193.77M$-205.54M$-158.56M$-231.23M$-316.86M$-372.09M$-88.09M$-554.23M$-515.74M$-9.00$-416.22M$-518.99M
Low Forecast$-24.32M$-21.93M$-20.37M$-21.48M$-30.02M$-27.07M$-25.15M$-26.51M$-29.83M$-26.90M$-24.99M$-41.39M$-79.44M$-87.78M$-88.69M$-90.96M$-123.63M$-172.21M$-193.77M$-205.54M$-211.41M$-231.23M$-316.86M$-372.09M$-88.09M$-554.23M$-515.74M$-14.00$-416.22M$-518.99M
Surprise %--------------------0.05%0.01%-0.04%-0.10%0.02%-0.01%1280181.82%-0.01%-0.06%

Clene's average Quarter net income forecast for Mar 23 is $-372.09M, with a range of $-372.09M to $-372.09M. CLNN's average Quarter net income forecast represents a -4419.15% decrease compared to the company's last Quarter net income of $8.62M (Dec 22).

Clene SG&A Forecast

Dec 28Sep 28Jun 28Mar 28Dec 27Sep 27Jun 27Mar 27Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21
# Analysts111122222222111124212111111111
SG&A--------------------$3.32M$3.67M-$3.18M$4.26M$3.34M$4.19M$4.38M$2.07M$4.40M
Avg Forecast$5.62M$5.31M$5.01M$4.73M$4.46M$4.21M$3.98M$3.76M$3.54M$3.35M$3.16M$2.98M$1.09M$1.09M$1.09M$1.09M$3.14M$2.34M$2.63M$3.56M$3.17M$2.98M$2.58M$2.94M$3.96M$1.90M$1.82M$4.00$2.55M$2.55M
High Forecast$5.62M$5.31M$5.01M$4.73M$4.46M$4.21M$3.98M$3.76M$3.54M$3.35M$3.16M$2.98M$1.09M$1.09M$1.09M$1.09M$3.14M$2.34M$2.63M$3.56M$3.63M$2.98M$2.58M$2.94M$3.96M$1.90M$1.82M$5.00$2.55M$2.55M
Low Forecast$5.62M$5.31M$5.01M$4.73M$4.46M$4.21M$3.98M$3.76M$3.54M$3.35M$3.16M$2.98M$1.09M$1.09M$1.09M$1.09M$3.14M$2.12M$2.63M$3.55M$2.72M$2.98M$2.58M$2.94M$3.96M$1.90M$1.82M$3.00$2.55M$2.55M
Surprise %--------------------1.05%1.23%-1.08%1.07%1.76%2.30%1093750.00%0.81%1.73%

Clene's average Quarter SG&A projection for Mar 24 is $3.56M, based on 1 Wall Street analysts, with a range of $3.55M to $3.56M. The forecast indicates a 7.10% rise compared to CLNN last annual SG&A of $3.32M (Dec 23).

Clene EPS Forecast

Dec 28Sep 28Jun 28Mar 28Dec 27Sep 27Jun 27Mar 27Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21
# Analysts111122222222111124212111111111
EPS--------------------$-0.08$-0.02-$-0.18$0.13$-0.19$0.06$-0.22$0.07$0.47
Avg Forecast$-0.19$-0.17$-0.16$-0.17$-0.23$-0.21$-0.20$-0.21$-0.23$-0.21$-0.19$-0.32$-0.62$-0.68$-0.69$-0.71$-0.96$-1.33$-1.51$-1.60$-1.44$-1.80$-2.47$-2.90$-0.69$-4.31$-4.01$-3.90$-3.24$-4.04
High Forecast$-0.19$-0.17$-0.16$-0.17$-0.23$-0.21$-0.20$-0.21$-0.23$-0.21$-0.19$-0.32$-0.62$-0.68$-0.69$-0.71$-0.96$-1.31$-1.51$-1.60$-1.23$-1.80$-2.47$-2.90$-0.69$-4.31$-4.01$-3.90$-3.24$-4.04
Low Forecast$-0.19$-0.17$-0.16$-0.17$-0.23$-0.21$-0.20$-0.21$-0.23$-0.21$-0.19$-0.32$-0.62$-0.68$-0.69$-0.71$-0.96$-1.34$-1.51$-1.60$-1.65$-1.80$-2.47$-2.90$-0.69$-4.31$-4.01$-3.90$-3.24$-4.04
Surprise %--------------------0.06%0.01%-0.06%-0.19%0.04%-0.02%0.06%-0.02%-0.12%

According to 1 Wall Street analysts, Clene's projected average Quarter EPS for Mar 23 is $-2.90, with a low estimate of $-2.90 and a high estimate of $-2.90. This represents a -2328.08% decrease compared to CLNN previous annual EPS of $0.13 (Dec 22).

Clene Peer Comparison by Price Target


TickerCompanyLast Closing PriceAvg Price TargetUpside/DownsideAvg Rating
IPSCCentury Therapeutics$1.26$20.001487.30%Buy
NGMNGM Biopharmaceuticals$1.54$16.50971.43%Buy
SNSESensei Biotherapeutics$0.52$5.50957.69%Buy
NKTXNkarta$3.23$21.60568.73%Buy
HOWLWerewolf Therapeutics$2.26$12.00430.97%Buy
MOLNMolecular Partners$6.06$29.00378.55%Buy
NUVBNuvation Bio$2.29$6.75194.76%Buy
ELYMEliem Therapeutics$5.11$13.00154.40%Buy
KZRKezar Life Sciences$7.09$17.50146.83%Buy
IMNMImmunome$12.81$30.33136.77%Buy
NXTCNextCure$1.31$3.00129.01%Buy
MLYSMineralys Therapeutics$13.50$30.00122.22%Buy
FHTXFoghorn Therapeutics$8.24$16.3398.18%Buy
CLNNClene$5.67$10.0076.37%Buy
GRPHLENZ Therapeutics$3.18$4.0025.79%Hold
IKNAIkena Oncology$1.72$1.33-22.67%Buy
CYTCyteir Therapeutics$3.02$2.00-33.77%Sell

CLNN Forecast FAQ


Yes, according to 6 Wall Street analysts, Clene (CLNN) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 6 'Buy' recommendations, accounting for 100.00% of CLNN's total ratings.

Clene (CLNN) average price target is $10 with a range of $10 to $10, implying a 76.37% from its last price of $5.67. The data is based on 6 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

According to Wall Street analysts' prediction for CLNN stock, the company can go up by 76.37% (from the last price of $5.67 to the average price target of $10), up by 76.37% based on the highest stock price target, and up by 76.37% based on the lowest stock price target.

CLNN's average twelve months analyst stock price target of $10 supports the claim that Clene can reach $9 in the near future.

Clene's analysts financial forecasts for the fiscal year (Dec 2027) are as follows: average revenue is $749.58K (high $749.58K, low $749.58K), average EBITDA is $-450K (high $-450K, low $-450K), average net income is $-109M (high $-109M, low $-109M), average SG&A $16.41M (high $16.41M, low $16.41M), and average EPS is $-0.847 (high $-0.847, low $-0.847). CLNN's analysts financial forecasts for the fiscal year (Dec 2028) are as follows: average revenue is $943.89K (high $943.89K, low $943.89K), average EBITDA is $-566K (high $-566K, low $-566K), average net income is $-88.1M (high $-88.1M, low $-88.1M), average SG&A $20.67M (high $20.67M, low $20.67M), and average EPS is $-0.686 (high $-0.686, low $-0.686).

Based on Clene's last annual report (Dec 2023), the company's revenue was $654K, beating the average analysts forecast of $533K by 22.70%. Apple's EBITDA was $-40.54M, beating the average prediction of $-320K by 12576.71%. The company's net income was $-49.504M, missing the average estimation of $-1.105B by -95.52%. Apple's SG&A was $14.42M, beating the average forecast of $11.67M by 23.55%. Lastly, the company's EPS was $-0.0005, missing the average prediction of $-8.603 by -99.99%. In terms of the last quarterly report (Dec 2023), Clene's revenue was $170K, beating the average analysts' forecast of $145K by 17.24%. The company's EBITDA was $-9.508M, beating the average prediction of $-87K by 10828.74%. Clene's net income was $-10.173M, missing the average estimation of $-185M by -94.50%. The company's SG&A was $3.32M, beating the average forecast of $3.17M by 4.64%. Lastly, the company's EPS was $-0.0792, missing the average prediction of $-1.44 by -94.50%